


## HLA-DR Antibody (MHC II) [clone IPO-10] (V2583)

Catalog No.	Formulation	Size
V2583-100UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	100 ug
V2583-20UG	0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide	20 ug
V2583SAF-100UG	1 mg/ml in 1X PBS; BSA free, sodium azide free	100 ug

[Bulk quote request](#)

<b>Availability</b>	1-3 business days
<b>Species Reactivity</b>	Human
<b>Format</b>	Purified
<b>Host</b>	Mouse
<b>Clonality</b>	Monoclonal (mouse origin)
<b>Isotype</b>	Mouse IgG3, kappa
<b>Clone Name</b>	IPO-10
<b>Purity</b>	Protein G affinity chromatography
<b>UniProt</b>	P01903
<b>Localization</b>	Cell surface
<b>Applications</b>	Flow Cytometry : 1-2ug/10 <sup>6</sup> cells Immunofluorescence : 1-2ug/ml
<b>Limitations</b>	This HLA-DR antibody is available for research use only.



SDS-PAGE Analysis of Purified, BSA-Free HLA-DR Antibody (clone IPO-10).  
Confirmation of Integrity and Purity of the Antibody.

## Description

mAb IPO-10 defines the antigen, which appears on B cell progenitors following HLA-DR and preceding CD10, CD19, CD22, CD37 and cym. It is expressed on resting B cells and then reappears and persists in cytoplasm and on cell surface until cytoplasmic Ig appears. It is a useful antibody for diagnostics of neoplasms of B cell origins. It reacts with human B cell lines Daudi, Raji, Namalva, EB-3, RPMI-8226 (50% of cells). The mAb does not label T cell lines, blood granulocytes, thymocytes or bone marrow stromal fibroblasts. No significant changes are detected after PHA or ConA stimulation while LPS and PWM stimulated cultures after 18-48h show decreased number of antigen-positive cells but in final terms of cultivation antigen is expressed again. This mAb labels B cell leukemias and some lymphomas. Hairy cell leukemia strongly reacts and 70% of B cell CLL and some B-NHL were also positive. IPO-10 reacts with AMML cells and in a majority of Hodgkin's disease cases a significant percentage of affected lymph node cells were detected.

## Application Notes

Optimal dilution of the HLA-DR antibody should be determined by the researcher.

## Immunogen

Spleen cells from a patient with hairy cell leukemia were used as the immunogen for the HLA-DR antibody.

## Storage

Store the HLA-DR antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).